Key Facts Surrounding This News Item
- ERYP had returned 0.00% year-to-date leading up to today’s news, versus a +17.14% return from the benchmark S&P 500 during the same period.
More Info About Erytech Pharma S.A. (ERYP)
ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company was founded in 2004 and is based in Lyon, France. View our full ERYP ticker page with ratings, news, and more.